Clinical Burden and Health Care Resource Utilization Associated With Managing Sickle Cell Disease With Recurrent Vaso-occlusive Crises in England

•Sickle cell disease is associated with substantial clinical burden.•Mean age of death in patients with recurrent vaso-occlusive crises is 40.17 years.•Patients average 5.84 vaso-occlusive crises per year.•Patients with recurrent vaso-occlusive crises need more health care than controls.•Higher numb...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical therapeutics 2025-01, Vol.47 (1), p.29-36
Hauptverfasser: Udeze, Chuka, Ly, Nelly F., Ingleby, Fiona C., Fleming, Sophia D., Conner, Sarah C., Howard, Jo, Li, Nanxin, Shah, Farrukh
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 36
container_issue 1
container_start_page 29
container_title Clinical therapeutics
container_volume 47
creator Udeze, Chuka
Ly, Nelly F.
Ingleby, Fiona C.
Fleming, Sophia D.
Conner, Sarah C.
Howard, Jo
Li, Nanxin
Shah, Farrukh
description •Sickle cell disease is associated with substantial clinical burden.•Mean age of death in patients with recurrent vaso-occlusive crises is 40.17 years.•Patients average 5.84 vaso-occlusive crises per year.•Patients with recurrent vaso-occlusive crises need more health care than controls.•Higher numbers of vaso-occlusive crises increase clinical and economic burden. Sickle cell disease (SCD) is an inherited red blood cell disease caused by a mutation in the gene encoding the β-subunit of adult hemoglobin that leads to hemolysis, anemia, vaso-occlusive crises (VOCs), morbidity, and mortality. This study provides a real-world assessment of the clinical burden and health care resource utilization (HCRU) associated with SCD with recurrent VOCs in England. This retrospective study linked primary care records from the Clinical Practice Research Datalink database with secondary care records from the Hospital Episode Statistics database to identify patients with SCD with recurrent VOCs between July 1, 2008, and June 30, 2018. A VOC was defined as SCD with crisis, acute chest syndrome, or priapism. Eligible patients had SCD, ≥2 VOCs/year in any 2 consecutive years after a diagnosis of SCD, and ≥1 year of follow-up data from the index date. Patients were exact matched with 5 controls from the general population in the databases. Demographics were assessed at index. Mortality, clinical complications, and HCRU were summarized during follow-up. After applying eligibility criteria, 1117 patients with SCD with recurrent VOCs and 5585 controls were included in the study. Mean age at index was 25 years in both groups. The proportion of deaths (3.67% vs 0.68%; P < 0.001) and mortality rate (0.78 deaths per 100 person-years vs 0.16 deaths per 100 person-years) were substantially higher in patients with SCD with recurrent VOCs versus matched controls. Mean (standard deviation [SD]) age of death in patients with SCD with recurrent VOCs who died during the follow-up period was 40.17 (14.09) years. The mean (SD) rate of VOCs for patients with SCD with recurrent VOCs was 5.84 (12.50) per patient per year (PPPY) during follow-up. Compared with matched controls, patients with SCD with recurrent VOCs had substantially higher mean [SD] rates PPPY of inpatient hospitalizations (7.59 [14.50] vs 0.32 [2.71]), prescriptions (31.06 [60.62] vs 7.58 [27.77]), and outpatient visits (9.60 [10.69] vs 1.78 [4.18]). Older patients and those with increased numbers of VOCs had increased mortality,
doi_str_mv 10.1016/j.clinthera.2024.09.023
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3128320382</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0149291824002868</els_id><sourcerecordid>3128320382</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1902-9b0ff2d3a319909adcc964a8b7869bc9c90ca31e34fb69031524d57e13429fd03</originalsourceid><addsrcrecordid>eNqFkUFv1DAQhS1ERZfCXwBLXLgkjO1kEx-XUFqkVkiFAjfLsSdbL16ntZNK7b_gH-PVlh649DSH-ebN03uEvGVQMmDLD5vSeBemK4y65MCrEmQJXDwjC9Y2smCs-vWcLIBVsuCStYfkZUobABCy5i_IYR4MJPAF-dNlHWe0px_naDFQHSw9Re2nK9rpiPQC0zhHg_Ryct7d68mNga5SGo3TE1r602XyXAe9dmFNvznz2yPt0Hv6ySXUCffEBZo5RgwT_aHTWIzG-Dm524zGjCXqAj0Oa5-_vyIHg_YJXz_MI3L5-fh7d1qcfT350q3OCsOy80L2MAzcCi2YlCC1NUYuK932TbuUvZFGgsk7FNXQLyUIVvPK1g0yUXE5WBBH5P1e9zqONzOmSW1dMtm4DjjOSQnGW8FBtDyj7_5DNzmTkN2pnW7d8LauM9XsKRPHlCIO6jq6rY53ioHataY26rE1tWtNgVS5tXz55kF_7rdoH-_-1ZSB1R7AHMitw6iScRgMWhfRTMqO7sknfwHD-a13</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3152572855</pqid></control><display><type>article</type><title>Clinical Burden and Health Care Resource Utilization Associated With Managing Sickle Cell Disease With Recurrent Vaso-occlusive Crises in England</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Udeze, Chuka ; Ly, Nelly F. ; Ingleby, Fiona C. ; Fleming, Sophia D. ; Conner, Sarah C. ; Howard, Jo ; Li, Nanxin ; Shah, Farrukh</creator><creatorcontrib>Udeze, Chuka ; Ly, Nelly F. ; Ingleby, Fiona C. ; Fleming, Sophia D. ; Conner, Sarah C. ; Howard, Jo ; Li, Nanxin ; Shah, Farrukh</creatorcontrib><description>•Sickle cell disease is associated with substantial clinical burden.•Mean age of death in patients with recurrent vaso-occlusive crises is 40.17 years.•Patients average 5.84 vaso-occlusive crises per year.•Patients with recurrent vaso-occlusive crises need more health care than controls.•Higher numbers of vaso-occlusive crises increase clinical and economic burden. Sickle cell disease (SCD) is an inherited red blood cell disease caused by a mutation in the gene encoding the β-subunit of adult hemoglobin that leads to hemolysis, anemia, vaso-occlusive crises (VOCs), morbidity, and mortality. This study provides a real-world assessment of the clinical burden and health care resource utilization (HCRU) associated with SCD with recurrent VOCs in England. This retrospective study linked primary care records from the Clinical Practice Research Datalink database with secondary care records from the Hospital Episode Statistics database to identify patients with SCD with recurrent VOCs between July 1, 2008, and June 30, 2018. A VOC was defined as SCD with crisis, acute chest syndrome, or priapism. Eligible patients had SCD, ≥2 VOCs/year in any 2 consecutive years after a diagnosis of SCD, and ≥1 year of follow-up data from the index date. Patients were exact matched with 5 controls from the general population in the databases. Demographics were assessed at index. Mortality, clinical complications, and HCRU were summarized during follow-up. After applying eligibility criteria, 1117 patients with SCD with recurrent VOCs and 5585 controls were included in the study. Mean age at index was 25 years in both groups. The proportion of deaths (3.67% vs 0.68%; P &lt; 0.001) and mortality rate (0.78 deaths per 100 person-years vs 0.16 deaths per 100 person-years) were substantially higher in patients with SCD with recurrent VOCs versus matched controls. Mean (standard deviation [SD]) age of death in patients with SCD with recurrent VOCs who died during the follow-up period was 40.17 (14.09) years. The mean (SD) rate of VOCs for patients with SCD with recurrent VOCs was 5.84 (12.50) per patient per year (PPPY) during follow-up. Compared with matched controls, patients with SCD with recurrent VOCs had substantially higher mean [SD] rates PPPY of inpatient hospitalizations (7.59 [14.50] vs 0.32 [2.71]), prescriptions (31.06 [60.62] vs 7.58 [27.77]), and outpatient visits (9.60 [10.69] vs 1.78 [4.18]). Older patients and those with increased numbers of VOCs had increased mortality, frequency of clinical complications, and HCRU. Despite currently available care, patients with SCD with recurrent VOCs in England have increased mortality, substantial clinical complications, and significant HCRU driven by VOCs and hospitalizations. Elevated mortality and clinical complications in patients with SCD with recurrent VOCs highlight the need for novel therapies in this space.</description><identifier>ISSN: 0149-2918</identifier><identifier>ISSN: 1879-114X</identifier><identifier>EISSN: 1879-114X</identifier><identifier>DOI: 10.1016/j.clinthera.2024.09.023</identifier><identifier>PMID: 39510902</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Age ; Anemia, Sickle Cell - complications ; Anemia, Sickle Cell - therapy ; Clinical complications ; Cost of Illness ; Databases, Factual ; Demographics ; Economics ; Emergency medical care ; England - epidemiology ; Erythrocytes ; Ethnicity ; Fatalities ; Female ; Genital diseases ; Health care ; Health care resource utilization ; Health economics ; Health Resources - statistics &amp; numerical data ; Health services utilization ; Hemoglobin ; Hospitalization ; Humans ; Male ; Medical records ; Middle Aged ; Morbidity ; Mortality ; Patient Acceptance of Health Care - statistics &amp; numerical data ; Patients ; Primary care ; Recurrence ; Resource utilization ; Retrospective Studies ; Sickle cell disease ; Socioeconomic factors ; Socioeconomic status ; Vaso-occlusive crisis ; Young Adult</subject><ispartof>Clinical therapeutics, 2025-01, Vol.47 (1), p.29-36</ispartof><rights>2024 Vertex Pharmaceuticals Funded the Research</rights><rights>Copyright © 2024 Vertex Pharmaceuticals Funded the Research. Published by Elsevier Inc. All rights reserved.</rights><rights>2024. Vertex Pharmaceuticals Funded the Research</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1902-9b0ff2d3a319909adcc964a8b7869bc9c90ca31e34fb69031524d57e13429fd03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0149291824002868$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39510902$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Udeze, Chuka</creatorcontrib><creatorcontrib>Ly, Nelly F.</creatorcontrib><creatorcontrib>Ingleby, Fiona C.</creatorcontrib><creatorcontrib>Fleming, Sophia D.</creatorcontrib><creatorcontrib>Conner, Sarah C.</creatorcontrib><creatorcontrib>Howard, Jo</creatorcontrib><creatorcontrib>Li, Nanxin</creatorcontrib><creatorcontrib>Shah, Farrukh</creatorcontrib><title>Clinical Burden and Health Care Resource Utilization Associated With Managing Sickle Cell Disease With Recurrent Vaso-occlusive Crises in England</title><title>Clinical therapeutics</title><addtitle>Clin Ther</addtitle><description>•Sickle cell disease is associated with substantial clinical burden.•Mean age of death in patients with recurrent vaso-occlusive crises is 40.17 years.•Patients average 5.84 vaso-occlusive crises per year.•Patients with recurrent vaso-occlusive crises need more health care than controls.•Higher numbers of vaso-occlusive crises increase clinical and economic burden. Sickle cell disease (SCD) is an inherited red blood cell disease caused by a mutation in the gene encoding the β-subunit of adult hemoglobin that leads to hemolysis, anemia, vaso-occlusive crises (VOCs), morbidity, and mortality. This study provides a real-world assessment of the clinical burden and health care resource utilization (HCRU) associated with SCD with recurrent VOCs in England. This retrospective study linked primary care records from the Clinical Practice Research Datalink database with secondary care records from the Hospital Episode Statistics database to identify patients with SCD with recurrent VOCs between July 1, 2008, and June 30, 2018. A VOC was defined as SCD with crisis, acute chest syndrome, or priapism. Eligible patients had SCD, ≥2 VOCs/year in any 2 consecutive years after a diagnosis of SCD, and ≥1 year of follow-up data from the index date. Patients were exact matched with 5 controls from the general population in the databases. Demographics were assessed at index. Mortality, clinical complications, and HCRU were summarized during follow-up. After applying eligibility criteria, 1117 patients with SCD with recurrent VOCs and 5585 controls were included in the study. Mean age at index was 25 years in both groups. The proportion of deaths (3.67% vs 0.68%; P &lt; 0.001) and mortality rate (0.78 deaths per 100 person-years vs 0.16 deaths per 100 person-years) were substantially higher in patients with SCD with recurrent VOCs versus matched controls. Mean (standard deviation [SD]) age of death in patients with SCD with recurrent VOCs who died during the follow-up period was 40.17 (14.09) years. The mean (SD) rate of VOCs for patients with SCD with recurrent VOCs was 5.84 (12.50) per patient per year (PPPY) during follow-up. Compared with matched controls, patients with SCD with recurrent VOCs had substantially higher mean [SD] rates PPPY of inpatient hospitalizations (7.59 [14.50] vs 0.32 [2.71]), prescriptions (31.06 [60.62] vs 7.58 [27.77]), and outpatient visits (9.60 [10.69] vs 1.78 [4.18]). Older patients and those with increased numbers of VOCs had increased mortality, frequency of clinical complications, and HCRU. Despite currently available care, patients with SCD with recurrent VOCs in England have increased mortality, substantial clinical complications, and significant HCRU driven by VOCs and hospitalizations. Elevated mortality and clinical complications in patients with SCD with recurrent VOCs highlight the need for novel therapies in this space.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age</subject><subject>Anemia, Sickle Cell - complications</subject><subject>Anemia, Sickle Cell - therapy</subject><subject>Clinical complications</subject><subject>Cost of Illness</subject><subject>Databases, Factual</subject><subject>Demographics</subject><subject>Economics</subject><subject>Emergency medical care</subject><subject>England - epidemiology</subject><subject>Erythrocytes</subject><subject>Ethnicity</subject><subject>Fatalities</subject><subject>Female</subject><subject>Genital diseases</subject><subject>Health care</subject><subject>Health care resource utilization</subject><subject>Health economics</subject><subject>Health Resources - statistics &amp; numerical data</subject><subject>Health services utilization</subject><subject>Hemoglobin</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Male</subject><subject>Medical records</subject><subject>Middle Aged</subject><subject>Morbidity</subject><subject>Mortality</subject><subject>Patient Acceptance of Health Care - statistics &amp; numerical data</subject><subject>Patients</subject><subject>Primary care</subject><subject>Recurrence</subject><subject>Resource utilization</subject><subject>Retrospective Studies</subject><subject>Sickle cell disease</subject><subject>Socioeconomic factors</subject><subject>Socioeconomic status</subject><subject>Vaso-occlusive crisis</subject><subject>Young Adult</subject><issn>0149-2918</issn><issn>1879-114X</issn><issn>1879-114X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUFv1DAQhS1ERZfCXwBLXLgkjO1kEx-XUFqkVkiFAjfLsSdbL16ntZNK7b_gH-PVlh649DSH-ebN03uEvGVQMmDLD5vSeBemK4y65MCrEmQJXDwjC9Y2smCs-vWcLIBVsuCStYfkZUobABCy5i_IYR4MJPAF-dNlHWe0px_naDFQHSw9Re2nK9rpiPQC0zhHg_Ryct7d68mNga5SGo3TE1r602XyXAe9dmFNvznz2yPt0Hv6ySXUCffEBZo5RgwT_aHTWIzG-Dm524zGjCXqAj0Oa5-_vyIHg_YJXz_MI3L5-fh7d1qcfT350q3OCsOy80L2MAzcCi2YlCC1NUYuK932TbuUvZFGgsk7FNXQLyUIVvPK1g0yUXE5WBBH5P1e9zqONzOmSW1dMtm4DjjOSQnGW8FBtDyj7_5DNzmTkN2pnW7d8LauM9XsKRPHlCIO6jq6rY53ioHataY26rE1tWtNgVS5tXz55kF_7rdoH-_-1ZSB1R7AHMitw6iScRgMWhfRTMqO7sknfwHD-a13</recordid><startdate>202501</startdate><enddate>202501</enddate><creator>Udeze, Chuka</creator><creator>Ly, Nelly F.</creator><creator>Ingleby, Fiona C.</creator><creator>Fleming, Sophia D.</creator><creator>Conner, Sarah C.</creator><creator>Howard, Jo</creator><creator>Li, Nanxin</creator><creator>Shah, Farrukh</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>202501</creationdate><title>Clinical Burden and Health Care Resource Utilization Associated With Managing Sickle Cell Disease With Recurrent Vaso-occlusive Crises in England</title><author>Udeze, Chuka ; Ly, Nelly F. ; Ingleby, Fiona C. ; Fleming, Sophia D. ; Conner, Sarah C. ; Howard, Jo ; Li, Nanxin ; Shah, Farrukh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1902-9b0ff2d3a319909adcc964a8b7869bc9c90ca31e34fb69031524d57e13429fd03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age</topic><topic>Anemia, Sickle Cell - complications</topic><topic>Anemia, Sickle Cell - therapy</topic><topic>Clinical complications</topic><topic>Cost of Illness</topic><topic>Databases, Factual</topic><topic>Demographics</topic><topic>Economics</topic><topic>Emergency medical care</topic><topic>England - epidemiology</topic><topic>Erythrocytes</topic><topic>Ethnicity</topic><topic>Fatalities</topic><topic>Female</topic><topic>Genital diseases</topic><topic>Health care</topic><topic>Health care resource utilization</topic><topic>Health economics</topic><topic>Health Resources - statistics &amp; numerical data</topic><topic>Health services utilization</topic><topic>Hemoglobin</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Male</topic><topic>Medical records</topic><topic>Middle Aged</topic><topic>Morbidity</topic><topic>Mortality</topic><topic>Patient Acceptance of Health Care - statistics &amp; numerical data</topic><topic>Patients</topic><topic>Primary care</topic><topic>Recurrence</topic><topic>Resource utilization</topic><topic>Retrospective Studies</topic><topic>Sickle cell disease</topic><topic>Socioeconomic factors</topic><topic>Socioeconomic status</topic><topic>Vaso-occlusive crisis</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Udeze, Chuka</creatorcontrib><creatorcontrib>Ly, Nelly F.</creatorcontrib><creatorcontrib>Ingleby, Fiona C.</creatorcontrib><creatorcontrib>Fleming, Sophia D.</creatorcontrib><creatorcontrib>Conner, Sarah C.</creatorcontrib><creatorcontrib>Howard, Jo</creatorcontrib><creatorcontrib>Li, Nanxin</creatorcontrib><creatorcontrib>Shah, Farrukh</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Udeze, Chuka</au><au>Ly, Nelly F.</au><au>Ingleby, Fiona C.</au><au>Fleming, Sophia D.</au><au>Conner, Sarah C.</au><au>Howard, Jo</au><au>Li, Nanxin</au><au>Shah, Farrukh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Burden and Health Care Resource Utilization Associated With Managing Sickle Cell Disease With Recurrent Vaso-occlusive Crises in England</atitle><jtitle>Clinical therapeutics</jtitle><addtitle>Clin Ther</addtitle><date>2025-01</date><risdate>2025</risdate><volume>47</volume><issue>1</issue><spage>29</spage><epage>36</epage><pages>29-36</pages><issn>0149-2918</issn><issn>1879-114X</issn><eissn>1879-114X</eissn><abstract>•Sickle cell disease is associated with substantial clinical burden.•Mean age of death in patients with recurrent vaso-occlusive crises is 40.17 years.•Patients average 5.84 vaso-occlusive crises per year.•Patients with recurrent vaso-occlusive crises need more health care than controls.•Higher numbers of vaso-occlusive crises increase clinical and economic burden. Sickle cell disease (SCD) is an inherited red blood cell disease caused by a mutation in the gene encoding the β-subunit of adult hemoglobin that leads to hemolysis, anemia, vaso-occlusive crises (VOCs), morbidity, and mortality. This study provides a real-world assessment of the clinical burden and health care resource utilization (HCRU) associated with SCD with recurrent VOCs in England. This retrospective study linked primary care records from the Clinical Practice Research Datalink database with secondary care records from the Hospital Episode Statistics database to identify patients with SCD with recurrent VOCs between July 1, 2008, and June 30, 2018. A VOC was defined as SCD with crisis, acute chest syndrome, or priapism. Eligible patients had SCD, ≥2 VOCs/year in any 2 consecutive years after a diagnosis of SCD, and ≥1 year of follow-up data from the index date. Patients were exact matched with 5 controls from the general population in the databases. Demographics were assessed at index. Mortality, clinical complications, and HCRU were summarized during follow-up. After applying eligibility criteria, 1117 patients with SCD with recurrent VOCs and 5585 controls were included in the study. Mean age at index was 25 years in both groups. The proportion of deaths (3.67% vs 0.68%; P &lt; 0.001) and mortality rate (0.78 deaths per 100 person-years vs 0.16 deaths per 100 person-years) were substantially higher in patients with SCD with recurrent VOCs versus matched controls. Mean (standard deviation [SD]) age of death in patients with SCD with recurrent VOCs who died during the follow-up period was 40.17 (14.09) years. The mean (SD) rate of VOCs for patients with SCD with recurrent VOCs was 5.84 (12.50) per patient per year (PPPY) during follow-up. Compared with matched controls, patients with SCD with recurrent VOCs had substantially higher mean [SD] rates PPPY of inpatient hospitalizations (7.59 [14.50] vs 0.32 [2.71]), prescriptions (31.06 [60.62] vs 7.58 [27.77]), and outpatient visits (9.60 [10.69] vs 1.78 [4.18]). Older patients and those with increased numbers of VOCs had increased mortality, frequency of clinical complications, and HCRU. Despite currently available care, patients with SCD with recurrent VOCs in England have increased mortality, substantial clinical complications, and significant HCRU driven by VOCs and hospitalizations. Elevated mortality and clinical complications in patients with SCD with recurrent VOCs highlight the need for novel therapies in this space.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>39510902</pmid><doi>10.1016/j.clinthera.2024.09.023</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0149-2918
ispartof Clinical therapeutics, 2025-01, Vol.47 (1), p.29-36
issn 0149-2918
1879-114X
1879-114X
language eng
recordid cdi_proquest_miscellaneous_3128320382
source MEDLINE; Elsevier ScienceDirect Journals
subjects Adolescent
Adult
Age
Anemia, Sickle Cell - complications
Anemia, Sickle Cell - therapy
Clinical complications
Cost of Illness
Databases, Factual
Demographics
Economics
Emergency medical care
England - epidemiology
Erythrocytes
Ethnicity
Fatalities
Female
Genital diseases
Health care
Health care resource utilization
Health economics
Health Resources - statistics & numerical data
Health services utilization
Hemoglobin
Hospitalization
Humans
Male
Medical records
Middle Aged
Morbidity
Mortality
Patient Acceptance of Health Care - statistics & numerical data
Patients
Primary care
Recurrence
Resource utilization
Retrospective Studies
Sickle cell disease
Socioeconomic factors
Socioeconomic status
Vaso-occlusive crisis
Young Adult
title Clinical Burden and Health Care Resource Utilization Associated With Managing Sickle Cell Disease With Recurrent Vaso-occlusive Crises in England
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T16%3A14%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Burden%20and%20Health%20Care%20Resource%20Utilization%20Associated%20With%20Managing%20Sickle%20Cell%20Disease%20With%20Recurrent%20Vaso-occlusive%20Crises%20in%20England&rft.jtitle=Clinical%20therapeutics&rft.au=Udeze,%20Chuka&rft.date=2025-01&rft.volume=47&rft.issue=1&rft.spage=29&rft.epage=36&rft.pages=29-36&rft.issn=0149-2918&rft.eissn=1879-114X&rft_id=info:doi/10.1016/j.clinthera.2024.09.023&rft_dat=%3Cproquest_cross%3E3128320382%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3152572855&rft_id=info:pmid/39510902&rft_els_id=S0149291824002868&rfr_iscdi=true